Generation Bio Co (Generation Bio Co) Change In Receivables

: $-3.57 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Generation Bio Co's change in receivables for the quarter that ended in Dec. 2023 was $-3.30 Mil. It means Generation Bio Co's Accounts Receivable increased by $3.30 Mil from Sep. 2023 to Dec. 2023 .

Generation Bio Co's change in receivables for the fiscal year that ended in Dec. 2023 was $-3.57 Mil. It means Generation Bio Co's Accounts Receivable increased by $3.57 Mil from Dec. 2022 to Dec. 2023 .

Generation Bio Co's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Generation Bio Co's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Generation Bio Co's liquidation value for the three months ended in Dec. 2023 was $92.73 Mil.

Generation Bio Co Change In Receivables Historical Data

The historical data trend for Generation Bio Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generation Bio Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

0.84

0.45

-0.40

-3.57

Generation Bio Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-48.92	48.97	-0.32	-3.30

Generation Bio Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.57 Mil.

Generation Bio Co (NAS:GBIO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Generation Bio Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	2.878	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Generation Bio Co's accounts receivable are only considered to be worth 75% of book value:

Generation Bio Co's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	264.364	-	171.63	+	0.75 * 0	+	0.5 * 0
=	92.73

Generation Bio Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Generation Bio Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Generation Bio Co (Generation Bio Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generation Bio Co (NAS:GBIO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.generationbio.com

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases.

Executives

Dannielle Appelhans	director	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Rowland Charles A Jr	director	3338 LANCASHIRE RD, FURLONG PA 18925
Donald William Nicholson	director	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Anthony G. Quinn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPWY, STE. 250, AUSTIN TX 78746
Antoinette Paone	officer: CHIEF OPERATING OFFICER	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Yalonda Howze	officer: CHIEF LEGAL OFFICER	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Phillip Samayoa	officer: CHIEF STRATEGY OFFICER	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Jason P Rhodes	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates X, L.p.	10 percent owner	400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Matthew Stanton	officer: Chief Scientific Officer	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Douglas Kerr	officer: Chief Development Officer	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Geoff Mcdonough	director, 10 percent owner, officer: See Remarks	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Tracy Zimmermann	officer: Chief Development Officer	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Cooper Ronald Harold Wilfred	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Mark D. Angelino	officer: Chief Operating Officer	GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142